Radioiodide (131I) therapy for the treatment of canine thyroid carcinoma

被引:48
|
作者
Worth, AJ
Zuber, RM
Hocking, M
机构
[1] Massey Univ, Vet Teaching Hosp, Ctr Compan Anim Hlth, Palmerston North, New Zealand
[2] Gladesville Vet Hosp, Gladesville, NSW 2111, Australia
关键词
D O I
10.1111/j.1751-0813.2005.tb11650.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective To assess the efficacy of radioactive iodine treatment (I-131) for canine thyroid carcinoma, as both the sole therapeutic modality and as an adjunct to surgery. Design Retrospective analysis of case records from the Gladesville Veterinary Hospital Nuclear Medicine Service, Sydney, between August 1988 and December 2001. Case Details The records of 65 dogs with thyroid carcinoma were analysed according to therapy and outcome. Forty-three dogs received radioiodide therapy, either as the sole therapeutic modality (32) or as an adjunct to surgery (11). Radioisotope therapy consisted of one to three doses of I-131 with a dose range of 555 to 1850 MBq. For analysis, dogs were divided into groups according to therapy: no treatment, surgery alone, surgery with radioiodide therapy or radioiodide therapy alone. Mode of therapy, dosage of I-131, clinical staging and age were all independently analysed according to survival to compare efficacy or predictive value respectively. Results When radioiodide therapy was used as an adjunct to surgery, median survival was 34 months. Censored median survival time for dogs that received radioiodide alone was 30 months. Dogs that did not receive treatment had a median survival of only 3 months. Log rank statistical analysis indicated that mode of therapy was significantly correlated with survival but that clinical stage of disease was not. Conclusion The authors conclude that I-131 therapy is effective at extending survival time, both as a sole therapeutic modality and as an adjunct to surgery, in dogs with invasive canine thyroid carcinoma. Incomplete surgical resection may not prolong survival in dogs also receiving I-131 therapy, however surgical resection with curative intent should be recommended as the first line of therapy for mobile thyroid carcinomas. Radioisotope therapy can be recommended for cases where surgery alone is considered unlikely to be curative because of metastatic disease or local invasion, or for cases where surgery has been attempted but complete surgical removal has not been achieved.
引用
收藏
页码:208 / 214
页数:7
相关论文
共 50 条
  • [1] Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma
    Verburg, Frederik A.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (03): : 253 - 257
  • [2] Thyroid carcinoma with high levels of function:: Treatment with 131I
    Sisson, JC
    Carey, JE
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (06) : 975 - 983
  • [3] Hemodialysis in patients requiring 131I treatment for thyroid carcinoma
    Fofi, Claudia
    Festuccia, Francescaromana
    Barberi, Simona
    Apponi, Francesca
    Chiacchiararelli, Laura
    Scopinaro, Francesco
    Punzo, Giorgio
    Mene, Paolo
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2013, 36 (06): : 439 - 443
  • [4] The evolving role of 131I for the treatment of differentiated thyroid carcinoma
    Robbins, RJ
    Schlumberger, MJ
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 28S - 37S
  • [5] Management of thyroid carcinoma with radioactive 131I
    International Journal of Radiation Oncology, Biology, Physics, 1996, 36 (01):
  • [6] TREATMENT OF THYROID CARCINOMA WITH 131I - NEW INFORMATION ON SURVIVAL AND METHOD OF TREATMENT
    VARMA, VM
    BEIERWAL.WH
    NISHSYAM.RH
    JOURNAL OF NUCLEAR MEDICINE, 1969, 10 (06) : 378 - &
  • [8] 131I therapy of thyroid cancer patients
    Reiners, C
    Farahati, J
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE, 1999, 43 (04): : 324 - 335
  • [9] Value of thyroglobulin to 131I uptake ratio in selection of initial therapy dose of 131I in patients with differentiated thyroid carcinoma
    Gerali, S
    Koutsikos, J
    Tsiouris, S
    Mainta, E
    Lucchetti, S
    Papathanasiou, G
    Fotinaki, E
    Makripoulias, V
    Kotsias, D
    Palestidis, C
    Zerva, C
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S425 - S425
  • [10] Value of thyroglobulin to 131I uptake ratio in selection of initial therapy dose of 131I in patients with differentiated thyroid carcinoma
    Zerva, C.
    Koutsikos, J.
    Palestidis, C.
    Kounadi, E.
    Gerali, S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 50 (04): : 348 - 354